Regeneron initiated at outperform at Leerink on strength of Dupixent, Eylea, and pipeline
franckreporter/iStock via Getty Images


Leerink has initiated Regeneron Pharmaceuticals (NASDAQ:REGN) with an outperform rating citing the company's strong sales of Dupixent (dupilumab) and Eylea (aflibercept).
The firm has a $738 price target (~12% upside based on Friday's close).
Analyst David Risinger said that he sees success for high-dose Eylea in the second half of 2022 and Dupixent for chronic obstructive pulmonary disease in 2023.

He added Eylea will see profit improvement in the future thanks to manufacturing yield improvements.
Risinger is also expecting updates on five oncology candidates this year.
Read why Seeking Alpha contributor Cappuccino Finance says that Regeneron's (REGN) future is bright due to its pipeline and cash flow.